1524P - Combination of three cytotoxic agents in small cell lung cancer

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Anticancer agents
Small Cell Lung Cancer
Biological Therapy
Presenter Georgios Stathopoulos
Authors G.T. Stathopoulos1, D. Traphalis1, J. Dimitroulis2, C. Kosmas3, J. Stathopoulos1, D. Tsavdaridis4
  • 1A' Oncology Clinic Errikos Dunant, Dr. Georgios Stathopoulos, 115 28 - Athens/GR
  • 26th Pneumonic Clinic, Hospital for thoracic disease, Athens/GR
  • 3Oncology Clinic, Anticancer Hospital Piraeus, Piraeus/GR
  • 4Oncology Clinic, Anticancer Hospital, Thessaloniki/GR



Small-cell lung cancer treatment has been tested by using combinations of several cytotoxic agents. For quite a number of years, the established treatment has been cisplatin and etoposide as the most effective chemotherapy regimen. Paclitaxel has also been used in combination with cisplatin and etoposide; the latter three - drug treatment has been effective but unacceptable due to toxicity.

Patients and methods

In the present trial we tested the aforementioned three-drug combination and avoided the toxicity in the majority of the patients by administering all 3 drugs on day 1 instead of on the established three days of treatment. Fifty patients were recruited from 5 oncology clinics. All patients had histologically- or cytologically- confirmed small-cell-lung cancer with limited and extensive disease in 40% and 60% of the patients respectively. Treatment was as follows: cisplatin 75mg/m2, etoposide 120mg/m2 with no dosage higher than 200mg/m2 and paclitaxel 135mg/m2. The agents were administered on day 1 and repeated every three weeks for 6 cycles in total.


The median survival was 14 months (95% CI 10.6-17.4) Forty-five patients (90%) achieved a response: 20(40%) patients a complete response and 25 (50%) a partial response. Adverse reactions was grade 3 and 4 neutropenia in 12% and 2% of the patients, respectively. Other side effects involved very low toxicity.


The one-day three-agent (cisplatin, etoposide, paclitaxel) treatment of small-cell lung cancer is beneficial with respect to response rate and survival, and has low and well-tolerated toxicity.


All authors have declared no conflicts of interest.